Stanford researchers call for drug labels to disclose lack of comparison with existing medications

Aug 12, 2009

The labeling information that comes with prescription drugs tells you what's known about the medication, but researchers from the Stanford University School of Medicine think it's high time that the labeling tell you what isn't known.

The researchers want the U.S. to require to state how new medications compare with similar, existing treatments. In many instance, these statements would indicate that there is no evidence that a new drug is more effective than older ones. They believe this information would make patients and health-care insurers less likely to pay for newer treatments without evidence that they lead to improved patient outcomes. It would also spur drug and medical-device companies to design more informative clinical trials to test a new product's superiority over existing therapies.

"Drug and device manufacturers benefit from an unacknowledged information gap that develops as more and more products are tested against placebo, but not each other," said Randall Stafford, MD, PhD, associate professor of medicine at the Stanford Prevention Research Center.

Stafford is the lead author of an essay that will be published online Aug. 12 in the , calling on the FDA to require more informative labeling of new drugs and medical devices. His co-authors are Philip Lavori, PhD, professor of health research and policy, and Todd Wagner, PhD, health economist at the Veterans Affairs Palo Alto and consulting assistant professor of health research and policy at the medical school.

The researchers note that the FDA doesn't require the inclusion of statements regarding how a new drug or device compares with existing treatments. Instead, treatments are simply required to perform better than a placebo without harmful side effects. "The problem is that the public, including physicians, often view as constituting more than it does," Stafford said. "There's an inherent tendency for physicians and patients to want the newest thing and to assume that newer and more expensive means better, although this is often not the case."

That would be fine if the new drugs were the same price as those already on the market, but new therapies "are almost always more costly than previously approved treatments, particularly so when existing drugs are available in generic form," the essay says.

The public's appetite for the latest drugs might be curbed if patients understood that new treatments aren't necessarily more effective than existing ones. The Stanford researchers recommend that the FDA require new treatments to carry a label that would read, for instance: "Although this drug has been shown to lower blood pressure more effectively than placebo, it has not been shown to be more effective than other members of the same class."

While some might argue that the FDA's primary role is informing the public about the safety of drugs and devices, the researchers believe that developing more informative labels is consistent with the agency's recently invigorated function as a public health agency.

Source: Stanford University Medical Center (news : web)

Explore further: Teva to lift bid for Mylan: report

Related Stories

Cost of diabetes treatment nearly doubled since 2001

Oct 27, 2008

Because of the increased number of patients, growing reliance on multiple medications and the shift toward more expensive new medicines, the annual cost of diabetes drugs nearly doubled in only six years, rising from $6.7 ...

Half of trials supporting FDA applications go unpublished

Sep 23, 2008

Over half of all supporting trials for FDA-approved drugs remained unpublished 5 years after approval, says new research published in this week's PLoS Medicine. The most important trials determining efficacy, and those with s ...

Drug class not effective for Alzheimer's

Oct 12, 2006

A study funded by the National Institute of Mental Health in Bethesda, Md., says antipsychotic drugs used to treat Alzheimer's patients are mostly ineffective.

Recommended for you

Teva to lift bid for Mylan: report

14 hours ago

Israeli pharmaceutical giant Teva plans to increase its bid for rival Mylan and could announce the move as soon as this week, according to a US media report Monday.

Vaccine for West Nile Virus enters human clinical trials

19 hours ago

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

FDA clears drug for leading form of cystic fibrosis

Jul 02, 2015

Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death. But it will ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.